Anavex Life Sciences Corp. (0HFR.L)
USD 8.21
(3.62%)
USD 8.21
(3.62%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -151.02 Million USD | -1.25% |
| 2022 | -149.15 Million USD | 1.94% |
| 2021 | -152.1 Million USD | -420.04% |
| 2020 | -29.24 Million USD | -31.84% |
| 2019 | -22.18 Million USD | 3.25% |
| 2018 | -22.93 Million USD | 16.43% |
| 2017 | -27.44 Million USD | -198.69% |
| 2016 | -9.18 Million USD | 39.58% |
| 2015 | -15.2 Million USD | -1026.04% |
| 2014 | -1.35 Million USD | -906.14% |
| 2013 | -134.21 Thousand USD | -146.66% |
| 2012 | 287.63 Thousand USD | -60.77% |
| 2011 | 733.21 Thousand USD | -67.09% |
| 2010 | 2.22 Million USD | 3.35% |
| 2009 | 2.15 Million USD | 39.64% |
| 2008 | 1.54 Million USD | 6174672.0% |
| 2007 | -25.00 USD | -100.32% |
| 2006 | 7725.00 USD | 890.69% |
| 2005 | -977.00 USD | 96.52% |
| 2004 | -28.11 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -138.75 Million USD | 0.45% |
| 2024 Q1 | -143.76 Million USD | 4.81% |
| 2024 Q2 | -139.38 Million USD | 3.05% |
| 2023 Q3 | -154.81 Million USD | -0.88% |
| 2023 Q4 | -151.02 Million USD | 2.45% |
| 2023 FY | -151.02 Million USD | -1.25% |
| 2023 Q1 | -143.62 Million USD | 3.71% |
| 2023 Q2 | -153.46 Million USD | -6.85% |
| 2022 Q3 | -153.19 Million USD | 0.09% |
| 2022 FY | -149.15 Million USD | 1.94% |
| 2022 Q4 | -149.15 Million USD | 2.64% |
| 2022 Q1 | -151.14 Million USD | 0.63% |
| 2022 Q2 | -153.34 Million USD | -1.45% |
| 2021 Q1 | -47.35 Million USD | -61.91% |
| 2021 FY | -152.1 Million USD | -420.04% |
| 2021 Q2 | -75.85 Million USD | -60.18% |
| 2021 Q3 | -157.56 Million USD | -107.7% |
| 2021 Q4 | -152.1 Million USD | 3.46% |
| 2020 Q1 | -27.45 Million USD | -23.77% |
| 2020 FY | -29.24 Million USD | -31.84% |
| 2020 Q2 | -26.56 Million USD | 3.26% |
| 2020 Q3 | -27.61 Million USD | -3.98% |
| 2020 Q4 | -29.24 Million USD | -5.9% |
| 2019 Q2 | -19.45 Million USD | 6.07% |
| 2019 Q1 | -20.71 Million USD | 9.66% |
| 2019 Q4 | -22.18 Million USD | -4.41% |
| 2019 FY | -22.18 Million USD | 3.25% |
| 2019 Q3 | -21.24 Million USD | -9.21% |
| 2018 Q4 | -22.93 Million USD | 11.22% |
| 2018 FY | -22.93 Million USD | 16.43% |
| 2018 Q3 | -25.82 Million USD | -0.67% |
| 2018 Q1 | -28.04 Million USD | -2.22% |
| 2018 Q2 | -25.65 Million USD | 8.53% |
| 2017 Q3 | -24.79 Million USD | -6.17% |
| 2017 Q4 | -27.44 Million USD | -10.68% |
| 2017 Q1 | -21.16 Million USD | -130.35% |
| 2017 FY | -27.44 Million USD | -198.69% |
| 2017 Q2 | -23.35 Million USD | -10.35% |
| 2016 FY | -9.18 Million USD | 39.58% |
| 2016 Q1 | -13.77 Million USD | 9.44% |
| 2016 Q2 | -11.86 Million USD | 13.86% |
| 2016 Q4 | -9.18 Million USD | 4.69% |
| 2016 Q3 | -9.63 Million USD | 18.74% |
| 2015 Q1 | -1.72 Million USD | -27.63% |
| 2015 Q3 | -7.91 Million USD | -30.09% |
| 2015 FY | -15.2 Million USD | -1026.04% |
| 2015 Q2 | -6.08 Million USD | -253.17% |
| 2015 Q4 | -15.2 Million USD | -92.04% |
| 2014 Q1 | 104.43 Thousand USD | 177.82% |
| 2014 Q2 | -8.99 Million USD | -8716.51% |
| 2014 Q3 | -7.97 Million USD | 11.35% |
| 2014 Q4 | -1.35 Million USD | 83.07% |
| 2014 FY | -1.35 Million USD | -906.14% |
| 2013 Q2 | 760.8 Thousand USD | 46.53% |
| 2013 Q3 | 755.95 Thousand USD | -0.64% |
| 2013 FY | -134.21 Thousand USD | -146.66% |
| 2013 Q1 | 519.21 Thousand USD | 80.51% |
| 2013 Q4 | -134.21 Thousand USD | -117.75% |
| 2012 Q2 | 1.02 Million USD | -10.89% |
| 2012 Q1 | 1.14 Million USD | 56.44% |
| 2012 FY | 287.63 Thousand USD | -60.77% |
| 2012 Q4 | 287.63 Thousand USD | 833.74% |
| 2012 Q3 | 30.8 Thousand USD | -96.99% |
| 2011 FY | 733.21 Thousand USD | -67.09% |
| 2011 Q4 | 733.21 Thousand USD | 285.74% |
| 2011 Q1 | -223.78 Thousand USD | -110.05% |
| 2011 Q3 | -394.75 Thousand USD | -301.04% |
| 2011 Q2 | 196.35 Thousand USD | 187.75% |
| 2010 FY | 2.22 Million USD | 3.35% |
| 2010 Q2 | 3.43 Million USD | 35.73% |
| 2010 Q3 | 2.1 Million USD | -38.69% |
| 2010 Q1 | 2.53 Million USD | 17.44% |
| 2010 Q4 | 2.22 Million USD | 5.75% |
| 2009 Q1 | 1.68 Million USD | 9.09% |
| 2009 Q4 | 2.15 Million USD | 21.02% |
| 2009 Q3 | 1.78 Million USD | -7.55% |
| 2009 Q2 | 1.92 Million USD | 14.41% |
| 2009 FY | 2.15 Million USD | 39.64% |
| 2008 Q3 | 1.29 Million USD | 93.79% |
| 2008 Q1 | 151.41 Thousand USD | 605772.0% |
| 2008 Q4 | 1.54 Million USD | 19.64% |
| 2008 FY | 1.54 Million USD | 6174672.0% |
| 2008 Q2 | 665.81 Thousand USD | 339.72% |
| 2007 Q4 | -25.00 USD | -100.01% |
| 2007 Q2 | 69.97 Thousand USD | 351.94% |
| 2007 Q1 | 15.48 Thousand USD | 100.44% |
| 2007 Q3 | 272.88 Thousand USD | 289.95% |
| 2007 FY | -25.00 USD | -100.32% |
| 2006 Q3 | 119.00 USD | 191.54% |
| 2006 Q2 | -130.00 USD | 0.0% |
| 2006 Q4 | 7725.00 USD | 6391.6% |
| 2006 FY | 7725.00 USD | 890.69% |
| 2006 Q1 | -130.00 USD | 86.69% |
| 2005 Q4 | -977.00 USD | 0.0% |
| 2005 FY | -977.00 USD | 96.52% |
| 2004 FY | -28.11 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | -46.695% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -383.788% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 176.25% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 573.652% |
| bluebird bio, Inc. | 108.57 Million USD | 239.102% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -1575.067% |
| Imunon, Inc. | -4.69 Million USD | -3113.774% |
| Editas Medicine, Inc. | -87.11 Million USD | -73.36% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 101.175% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 107.199% |
| Myriad Genetics, Inc. | 88.1 Million USD | 271.423% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 185.18% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -350.455% |
| Verastem, Inc. | -37.27 Million USD | -305.129% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 101.834% |
| Waters Corporation | 1.96 Billion USD | 107.704% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.563% |
| Biogen Inc. | 6.28 Billion USD | 102.402% |
| Nektar Therapeutics | 210.24 Million USD | 171.834% |
| Perrigo Company plc | 3.32 Billion USD | 104.546% |
| Dynavax Technologies Corporation | 106.63 Million USD | 241.627% |
| Illumina, Inc. | 1.21 Billion USD | 112.44% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 2267.37% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | -32.607% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 204.1% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 2201.35% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 139.875% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -2027.099% |
| Evolus, Inc. | 63.7 Million USD | 337.057% |
| Adicet Bio, Inc. | -142 Million USD | -6.349% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -310.347% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -457.284% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 132.924% |
| FibroGen, Inc. | 56.76 Million USD | 366.042% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 113.19% |
| OPKO Health, Inc. | 230.68 Million USD | 165.468% |
| Homology Medicines, Inc. | 18.43 Million USD | 919.135% |
| Geron Corporation | 14.76 Million USD | 1123.129% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 109.526% |
| Exelixis, Inc. | -73.05 Million USD | -106.741% |
| Viking Therapeutics, Inc. | -54.25 Million USD | -178.354% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | -35.567% |
| Zoetis Inc. | 4.76 Billion USD | 103.171% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 24.42% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -1399.593% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 98.421% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -936.399% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 114.325% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 115.596% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | -11.539% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 110.937% |
| Blueprint Medicines Corporation | 702.83 Million USD | 121.488% |
| Insmed Incorporated | 721.62 Million USD | 120.928% |
| TG Therapeutics, Inc. | 17.86 Million USD | 945.504% |
| Incyte Corporation | -3.17 Billion USD | 95.243% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 119.721% |